new-webinar-series-1

 

Webinar: Working with Mature, Chamber-Specific Cardiomyocytes

In North America: Tuesday 7 June 2022 at Noon EDT / 900 PDT (register here)

In Europe:  Tuesday, 7 June 2022 at Noon BST / 1300 CEST (register here)

 StemBioSys’ CELLvo™ Matrix Plus induces rapid and spontaneous maturation of iPSC-derived cardiomyocytes in vitro in monolayer culture. We have previously reported that this technology enables high-throughput, predictive cardiotoxicity testing by maturing cells in 96- and 384-well plate formats. Here, we discuss the next innovation in cardiomyocyte cell culture. StemBioSys will now offer chamber-specific cardiomyocytes that can be matured on CELLvo™ Matrix Plus to achieve a new level of specificity and nuance in in vitro assays. Chamber specific cardiomyocytes faithfully recreate, in vitro, nuances of the chambers that previously could not be well studied in cell culture.

About the speaker

30

 

 

Dr. Travis Block, Ph.D., earned his Ph.D. in the laboratory of Dr. Xiao-Dong Chen at the University of Texas Health Science Center before joining StemBioSys as Senior Scientist in 2016. Today, Dr. Block serves as Chief Technology Officer at StemBioSys. Dr. Block holds adjunct faculty appointments at the University of Texas at San Antonio, UT Health San Antonio, and Trinity University. In addition, he serves on the CELL-MET Industrial Partners Advisory Board, the University of Rochester Hajim School of Engineering Young Alumni Council, the UT Health Graduate School Alumni Council (Chair), and is on the Health and Environmental Sciences Cardiotoxicity Committee.